1 citations
,
October 2024 in “QJM” IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.
January 2012 in “Yearbook of Dermatology and Dermatologic Surgery” Acne treatment, including isotretinoin, improves quality of life and does not worsen depression.
July 2023 in “SKIN The Journal of Cutaneous Medicine” Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
July 2025 in “Journal of Investigative Dermatology” IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
13 citations
,
July 2019 in “Dermatologic therapy” Stopping adalimumab and starting methotrexate with topical treatments improved the woman's scalp psoriasis and hair regrew.
A 29-year-old woman with symptoms of both lupus and rheumatoid arthritis improved with specific medications.
7 citations
,
July 2023 in “Immunotherapy” Ritlecitinib works well and is safe for treating alopecia areata.
79 citations
,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
26 citations
,
January 2005 in “PubMed” RUM-loaded SLN shows promise for treating acne and hair loss topically.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
5 citations
,
January 2016 in “European Journal of Dermatology” Suplatast tosilate successfully treated a woman's systemic sclerosis symptoms.
3 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes” Low-dose Buserelin effectively reduces hirsutism with minimal side effects.
19 citations
,
September 2006 in “Journal of Pediatric Gastroenterology and Nutrition” Early use of infliximab in severe pediatric Crohn's disease can lead to significant improvement and remission.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab is safe for long-term use with low rates of major heart-related events.
1 citations
,
June 2016 in “Annals of the rheumatic diseases” Retinoids may help treat lupus nephritis and reduce steroid use.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
January 2018 in “Practical diabetes” Leflunomide is effective for rheumatoid arthritis but has significant side effects.
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
2 citations
,
June 2018 in “The Medical Journal of Cairo University/The Medical Journal of Cairo University” Platelet Rich Plasma reduces psoriasis symptoms but isn't enough alone for treatment.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine effectively treated ashy dermatosis in a patient.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
253 citations
,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.